Chemistry: molecular biology and microbiology – Animal cell – per se ; composition thereof; process of...
Reexamination Certificate
2001-06-29
2011-10-18
Kolker, Daniel E (Department: 1649)
Chemistry: molecular biology and microbiology
Animal cell, per se ; composition thereof; process of...
C435S347000, C435S377000, C530S350000
Reexamination Certificate
active
08039253
ABSTRACT:
A pharmaceutical for prevention and treatment of demyelination-associated neural function impairing diseases contains erythropoietin as an active ingredient, and protectively act on the survival of oligodendrocytes, which form a myelin sheath, in cerebrovascular dementia typified by multiple sclerosis and Binswanger disease, diseases involving demyelination. The pharmaceutical and method also promote maturation of undifferentiated oligodendrocytes present in the brain, activating remyelination. Through these mechanisms, the pharmaceutical and method can prevent and treat demyelination-associated neural function impairing diseases.
REFERENCES:
patent: 6165783 (2000-12-01), Weiss et al.
patent: 7410941 (2008-08-01), Brines et al.
patent: 1 072 609 (2001-01-01), None
patent: 5-246885 (1993-09-01), None
patent: WO 95/03821 (1995-02-01), None
patent: WO 99/21966 (1999-05-01), None
patent: WO 00/61164 (2000-10-01), None
Hart et al., Curr Opin Neurol 16: 375-383, 2003.
Stuve et al, Curr Opin Neurol 16: 393-401, 2003.
Cassan et al., J Neurochem 100: 883-892, 2007.
Schmandt et al Drug Dis Today Disease Models 3: 349-358, 2006.
Zhang et al., Br Res 1034: 34-39, 2005.
Fontoura et a. Int Rev Immunol 24: 415-446, 2005.
McFarland et al Nat Immunol 8: 913-919, 2007.
Stengel et al. Prog Neurobiol 68: 361-376, 2002.
Wells, 1990, Biochemistry 29:8509-8517.
Ngo et al., 1994, The Protein Folding Problem and Tertiary Structure Prediction, pp. 492-495.
Bork, 2000, Genome Research 10:398-400.
Skolnick et al., 2000, Trends in Biotech. 18(1):34-39.
Doerks et al., 1998, Trends in Genetics 14:248-250.
Smith et al., 1997, Nature Biotechnology 15:1222-1223.
Brenner, 1999, Trends in Genetics 15:132-133.
Bork et al., 1996, Trends in Genetics 12:425-427.
Stanislaus et al (Neurosc Lett 269: 71-74, 1999.
Tanaka et al. Brain Res 989: 172-179, 2003.
Zuccarello et al. Neurosc 144: 865-877, 2007.
Gensert et al.Neuron 19: 197-203, 1997.
Brines et al. PNAS 97: 10526-10531, 2000.
Pendlebury et al. Mag Res Imag 18: 369-378, 2000.
Tabira et al. (Int J Dev Neurosc 13: 241-252, 1995).
Mancardi et al. J Neuroimmunol 107: 178-183, 2000.
Al-Omaishi et al. J Leukoc Biol 65: 444-452, 1999.
Bernaudin, et al, “A Potential Role for Erythropoietin in Focal Permanent Cerebral Ischemia in Mice”, Journal of Cerebral Blood flow and Metabolism. 19:643-651. 1999.
Koshimura, et al, “Effects of Erythropoietin on Neuronal Activity”, Journal Neurochemistry. 72(6):2565-2572. 1999.
Masuda, et al, “In vitro neuroprotective action of recombinant rat erythropoietin produced by astrocyte cell lines nd comparative studies with erythropoietin produced by Chinese hamster ovary cells”. Cytotechnology, 29:207-213. 1999.
Sasaki, et al, “Novel physiological functions of erythropoietin an its biosynethesis regulation” Nippon Nogei Kagaku Kaishi, 72(12):1427-1437. 1998.
Asou Hiroaki
Sugawa Makoto
Browdy and Neimark PLLC
Chugai Seiyaku Kabushiki Kaisha
Dutt Aditi
Kolker Daniel E
Tokyo Metropolitan Institute of Gerontology
LandOfFree
Pharmaceutical for prevention and treatment of demyelinating... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical for prevention and treatment of demyelinating..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical for prevention and treatment of demyelinating... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4281995